Effects of isradipine, a new calcium antagonist, on maternal cardiovascular system and uterine activity in labour

Dag Wide-Swensson, Ingemar Ingemarsson, S Arulkumaran, Karl-Erik Andersson

Research output: Contribution to journalArticlepeer-review

Abstract

The effects of isradipine (a new calcium antagonist of the dihydropyridine type) on maternal blood pressure and heart rate, fetal heart rate, and uterine activity in labour were measured. Uterine activity was recorded by an intrauterine microtip transducer catheter connected to a fetal monitor. Isradipine was given as a slow injection in doses of 0.5 mg (10 women), 1 mg (11 women), and 1.5 mg (6 women). A reduction of systolic (6-16%) and diastolic (19-22%) blood pressure was seen, and concomitantly there was an increase in maternal (29-34%) and fetal (3-10%) heart rates. Reduction in uterine activity was not dose-related (maximum reduction 17%). Side effects (headache, palpitations) were minor and well tolerated. One women in the high-dose group had a shortlasting episode of hypotension. The results suggest that isradipine given as a bolus dose decreases blood pressure in pregnant women with little effects on uterine activity and fetal heart rate.
Original languageEnglish
Pages (from-to)945-949
JournalBritish Journal of Obstetrics and Gynaecology
Volume97
Issue number10
DOIs
Publication statusPublished - 1990

Subject classification (UKÄ)

  • Medicinal Chemistry
  • Pharmacology and Toxicology
  • Obstetrics, Gynecology and Reproductive Medicine

Fingerprint

Dive into the research topics of 'Effects of isradipine, a new calcium antagonist, on maternal cardiovascular system and uterine activity in labour'. Together they form a unique fingerprint.

Cite this